BUY Aurobindo Pharma — Rajesh Satpute, 08 Sept 2026

byRajesh SatputeHorizon: Intraday8 Sept 2026, 9:22 am ISTvia CNBC Awaaz.

Entry₹1,679.3Inferred

Target₹1,700

Stop loss₹1,660-1.15% risk

At expiry₹1,678.48 Sept 2026, 3:05 pm

Expired-0.05%

Follow Rajesh Satpute for new calls(8% target hit, 95 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 12 active Intraday picks this session

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Sept 2026

2 supporting4 neutral0 opposing

Supports the BUY call (2)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·8 Sept · today

Aurobindo stock gains on generic Advair launch

NewsGoogle News·1 Sept · 6d ago

Neutral / worth noting (4)

Upcoming Stock Split, Dividend, Bonus Issue THIS Week: Aurobindo Pharma, Muthoot Finance, More | Full List

NewsGoogle News·5 Sept · 3d ago

Aurobindo Pharma moves up as its arm incorporates wholly owned subsidiary

NewsGoogle News·2 Sept · 5d ago

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 6d ago

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 1w ago

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.